We are live on ! Find out more
GLUE icon

Monte Rosa Therapeutics
GLUE

104 hedge funds and large institutions have $423M invested in Monte Rosa Therapeutics in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 36 increasing their positions, 17 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,265% more call options, than puts

Call options by funds: $2.21M | Put options by funds: $162K

209% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 11

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

112% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 17

61% more capital invested

Capital invested by funds: $264M → $423M (+$160M)

28% more funds holding

Funds holding: 81 → 104 (+23)

18.19% more ownership

Funds ownership: 81.07% → 99.26% (+18%)

Holders
104
Holders Change
+23
Holders Change %
+28.4%
% of All Funds
1.37%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
34
Increased
36
Reduced
17
Closed
11
Calls
$2.21M
Puts
$162K
Net Calls
+$2.05M
Net Calls Change
+$1.32M

Top Buyers

Rank Fund Capital Flow
1
VVM
Versant Venture Management
California
+$42.4M
2
BI
BVF Inc
California
+$20.7M
3
Morgan Stanley
Morgan Stanley
New York
+$16M
4
BlackRock
BlackRock
New York
+$7.04M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$4.67M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$10.8M
2
SCM
Suvretta Capital Management
New York
-$8.22M
3
VPC
Vestal Point Capital
New York
-$3.79M
4
Citadel Advisors
Citadel Advisors
Florida
-$2.86M
5
ECM
ExodusPoint Capital Management
New York
-$2.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
26
Wellington Management Group
Massachusetts
$1.54M +$35.6K +4,740 +2%
TD Asset Management
27
TD Asset Management
Ontario, Canada
$1.53M +$198K +26,400 +14%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$1.18M +$27.2K +3,619 +2%
Goldman Sachs
29
Goldman Sachs
New York
$1.11M -$141K -18,731 -10%
JF
30
Jump Financial
Illinois
$1.07M +$1.16M +154,842 New
Dimensional Fund Advisors
31
Dimensional Fund Advisors
Texas
$1M +$41.6K +5,538 +4%
Manulife (Manufacturers Life Insurance)
32
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$815K -$3.49K -465 -0.4%
N
33
Nuveen
North Carolina
$714K – – –
A
34
AlphaQuest
New York
$657K +$710K +94,633 New
CSS
35
Cubist Systematic Strategies
Connecticut
$644K +$697K +92,818 New
BFM
36
Boothbay Fund Management
New York
$633K -$135 -18 -0%
Qube Research & Technologies (QRT)
37
Qube Research & Technologies (QRT)
United Kingdom
$601K +$649K +86,545 New
CC
38
Casdin Capital
New York
$597K – – –
American Century Companies
39
American Century Companies
Missouri
$533K +$124K +16,485 +27%
Barclays
40
Barclays
United Kingdom
$491K +$122K +16,233 +30%
Wells Fargo
41
Wells Fargo
California
$487K +$360K +47,952 +216%
D.E. Shaw & Co
42
D.E. Shaw & Co
New York
$487K +$389K +51,823 +283%
Bank of America
43
Bank of America
North Carolina
$439K -$76.1K -10,136 -14%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$429K +$70K +9,323 +18%
UBS Group
45
UBS Group
Switzerland
$412K +$256K +34,066 +134%
Millennium Management
46
Millennium Management
New York
$322K +$118K +15,749 +51%
Citigroup
47
Citigroup
New York
$311K +$111K +14,780 +49%
LCAM
48
Long Corridor Asset Management
Hong Kong
$278K – – –
Walleye Capital
49
Walleye Capital
New York
$275K +$298K +39,647 New
AllianceBernstein
50
AllianceBernstein
Tennessee
$244K – – –
1
2
3 4 5

GLUE Hedge Fund Activity: Q4 2024 in Review

104 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q4 2024, worth a combined $423M — up 61% from $264M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new GLUE positions and 11 closed out — a net gain of 23 holders — while 36 added to existing stakes and 17 trimmed.

The largest buyer was Versant Venture Management, opening a new position worth an estimated $42.4M. The largest seller was Avoro Capital Advisors, cutting an estimated $10.8M.

  • 104 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q4 2024, up from 81 in Q3 2024.
  • Funds reported $423M of Monte Rosa Therapeutics stock for Q4 2024, up 61% quarter-over-quarter.
  • 34 funds opened new Monte Rosa Therapeutics positions in Q4 2024 and 11 closed out, a net change of +23 holders.
  • The largest Monte Rosa Therapeutics buyer in Q4 2024 was Versant Venture Management, an estimated $42.4M added.
  • The largest Monte Rosa Therapeutics seller in Q4 2024 was Avoro Capital Advisors, an estimated $10.8M sold.

Based on aggregated 13F filings for Q4 2024.